NDASUBCUTANEOUSSOLUTION
Approved
Dec 2012
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
20
Mechanism of Action
Somatostatin Receptor Agonists
Pharmacologic Class:
Somatostatin Analog
Clinical Trials (5)
Study in Healthy Subjects to Investigate the Relative Bioavailability and Safety of Pasireotide After Single Subcutaneous Dose Administration Using a Reusable ServoPen With Cartridge as Compared to Administration Using a Syringe Drawn From an Ampule
Started Dec 2025
40 enrolled
PharmacokineticsSafety
Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor
Started Dec 2024
28 enrolled
Desmoplastic Small Round Cell TumorSynovial Sarcoma
A Study of Pasireotide in People With Prolactinoma
Started Feb 2024
10 enrolled
Prolactin-Producing Pituitary Tumor
Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
Started Jan 2024
93 enrolled
Post-Bariatric Hypoglycemia
Pasireotide in Hyperinsulinemic Hypoglycemia
Started Apr 2017
0Congenital HyperinsulinismInsulinomaHyperinsulinism
Loss of Exclusivity
LOE Date
Dec 14, 2026
9 months away
Patent Expiry
Dec 14, 2026
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 7473761 | Dec 14, 2026 | SubstanceProduct | — |